However, the IMspire150 trial showed that a triple combination with atezolizumab significantly prolonged PFS in patients with BRAF-mutated melanoma compared to a combination of vemurafenib (a BRAF inhibitor) and cobimetinib (15.1 months vs. 10.6 months, p = 0.025) (24). This evidence concerns the gene BRAF and melanoma.